0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma

Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma

Dr. Jiao Zhang, Ph.D. – Baylor College of Medicine, Houston TX

Read More
HBEGF as a novel therapeutic target for Diffuse Midline Glioma
Northeast, New York Julia Travagline 11/20/24 Northeast, New York Julia Travagline 11/20/24

HBEGF as a novel therapeutic target for Diffuse Midline Glioma

HBEGF as a novel therapeutic target for Diffuse Midline Glioma

Dr. Oren Becher, M.D. – Icahn School of Medicine at Mount Sinai, New York, NY

Read More
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
South, Texas Julia Travagline 11/20/24 South, Texas Julia Travagline 11/20/24

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma

Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX

Read More
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Midwest, Michigan Julia Travagline 11/20/24 Midwest, Michigan Julia Travagline 11/20/24

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT

Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI

Read More
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Northeast, Washington D.C. Julia Travagline 11/20/24 Northeast, Washington D.C. Julia Travagline 11/20/24

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis

Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.

Read More
Thyroid Hormone Induces Terminal Differentiation of Tumor Cells in Medulloblastoma
Northeast, Pennsylvania Julia Travagline 11/22/23 Northeast, Pennsylvania Julia Travagline 11/22/23

Thyroid Hormone Induces Terminal Differentiation of Tumor Cells in Medulloblastoma

Thyroid Hormone Induces Terminal Differentiation of Tumor Cells in Medulloblastoma

Dr. Zeng-jie Yang – The Research Institute of Fox Chase Cancer Center, Philadelphia, PA

Read More
Delineating molecular mechanisms of metastatic dissemination for medulloblastoma therapy
Pennsylvania, Northeast, Midwest Julia Travagline 11/22/23 Pennsylvania, Northeast, Midwest Julia Travagline 11/22/23

Delineating molecular mechanisms of metastatic dissemination for medulloblastoma therapy

Delineating molecular mechanisms of metastatic dissemination for medulloblastoma therapy

Dr. Baoli Hu – University of Pittsburgh, Pittsburgh, PA

Read More
Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma
California, West Julia Travagline 8/10/21 California, West Julia Travagline 8/10/21

Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma

Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma

Beckman Research Institute of the City of Hope, Duarte, CA

Read More
Defining Actionable Apoptotic Dependencies in Pediatric CNS Tumors
Massachusetts, Northeast Julia Travagline 8/9/21 Massachusetts, Northeast Julia Travagline 8/9/21

Defining Actionable Apoptotic Dependencies in Pediatric CNS Tumors

Defining Actionable Apoptotic Dependencies in Pediatric CNS Tumors

John B. Little Center for Radiation Sciences, Harvard Chan School, Boston, MA

Read More
MicroNRA Regulation of Cancer Stem Cells in Nervous System Tumors
Texas, South Julia Travagline 8/9/21 Texas, South Julia Travagline 8/9/21

MicroNRA Regulation of Cancer Stem Cells in Nervous System Tumors

MicroNRA Regulation of Cancer Stem Cells in Nervous System Tumors

Baylor College of Medicine, Houston, TX

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark